Table 1.
Characteristics, clinical background and medications of severe COVID-19 patients. HTN, Hypertension; DM, Diabetes Mellitus; IHD, Ischemic Heart Disease; CKD. Chronic Kidney Disease; CVA. Cerebro Vascular Accident; TIA, Transient Ischemic Attack; VTE, Venous Thrombo Embolism; Hx, History; NOAC, Novel Anti-Coagulant; ACEi, Angiotensin II converting enzyme inhibitor; ARB, Angiotensin II Receptor Blocker. None of the differences between the groups of normal or low FXIII was statistically significant. Normal FXIII activity was defined as activity level >79 %. Low FXIII levels were levels were defined as activity level <79 %
| FXIII activity | Overall (N=34) |
Normal (>79 %) (N=9) |
Low (<79 %) (N=25) |
|---|---|---|---|
| Age, median (range) | 57 (22-76) | 54 (42-67) | 59 (22-76) |
| Female gender | 10 (29 %) | 2 (22 %) | 8 (32 %) |
| HTN | 15 (44 %) | 6 (67 %) | 9 (36 %) |
| DM | 16 (47 %) | 6 (67 %) | 10 (40 %) |
| IHD | 4 (12 %) | 0 | 4 (16 %) |
| CKD | 3 (9 %) | 1 (11 %) | 2 (8 %) |
| Obesity | 17 (50 %) | 7 (78 %) | 10 (40 %) |
| Hx of CVA/TIA | 0 | 0 | 0 |
| Hx of VTE | 0 | 0 | 0 |
| Hx of Malignancy | 1(3 %) | 0 | 1 (4 %) |
| Acetylsalicylic acid | 6 (18 %) | 1 (11 %) | 5 (20 %) |
| P2Y12 inhibitors | 0 | 0 | 0 |
| NOACs | 0 | 0 | 0 |
| ACEi/ARB | 5 (15 %) | 1 (11 %) | 4 (16 %) |